Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
FACT II Acquisition Corp. provided an update on its trust account balance, which stood at approximately $189.38 million as of November 16, 2026. This results in an updated estimated redemption price of $10.82 per share for shareholders ahead of an upcoming extraordinary general meeting to vote on an extension.
Zoomcar Holdings completed the eighth closing of its private placement, issuing 100 Series A units for gross proceeds of $100,000. Each unit consists of one share of Series A Convertible Preferred Stock and a warrant to purchase 20,000 shares of common stock. The company has extended the termination date of the overall $5 million offering (plus a $5 million overallotment option) to November 30, 2026.
Vivani Medical entered into a share purchase agreement for a $5.1 million private placement of common stock with board members Gregg Williams and Aaron Mendelsohn. The shares were priced at $1.01 per share, representing an at-the-market transaction based on the prior trading day's close. Proceeds will be used to fund the clinical development of NPM-139, the company's semaglutide implant for weight maintenance.
Keurig Dr Pepper completed a public offering of 66,666,667 shares of common stock (including the full exercise of the underwriters' option) at a price of $34.50 per share. The company received approximately $2.25 billion in net proceeds, which it intends to use to repay outstanding debt and accelerate deleveraging. This financial move is intended to optimize the balance sheet ahead of the company's planned separation into two independent public companies in early 2027.
MapLight Therapeutics entered into a sales agreement with Leerink Partners to establish an at-the-market (ATM) offering program. The company may sell up to $100 million of its common stock from time to time, with Leerink acting as the sales agent for a commission of up to 3.0%.
Cyabra entered into a securities purchase agreement for a private placement of Series D Preferred Stock and warrants, consisting of an initial $15.6 million closing ($10 million in new cash and $5.6 million via debt cancellation). The agreement also contemplates additional tranches of up to $30 million over three years and the potential establishment of a $50 million equity line of credit.
iPower Inc. completed a fourth additional optional closing under its existing senior secured convertible note facility, issuing $2.0 million in principal amount of Series A Notes to an institutional investor. The company received gross proceeds of $1.88 million at a fixed conversion price of $1.488 per share, representing 120% of the recent Nasdaq closing price. To date, the company has sold $17.2 million in Series A Notes under the $30.0 million facility.
Super League Enterprise, Inc. entered into a securities purchase agreement with accredited investors for a registered direct offering of 150,000 shares of common stock. The offering is priced at $4.00 per share and is expected to result in gross proceeds of approximately $600,000. The transaction is conducted under the company's existing shelf registration statement and is scheduled to close around November 16, 2026.
Arcturus Therapeutics Holdings Capital Raise of $50M
Arcturus Therapeutics entered into a securities purchase agreement with Meiji Seika Pharma for the sale of 2,466,395 shares of common stock at $20.27 per share, raising $50 million in gross proceeds. The investment was made at an 80% premium to the 30-day average closing price and is part of an expanded collaboration including a license agreement for ARCT-154 technology and a pandemic preparedness MOU in Japan.
Value
$50M
Counterparty
Meiji Seika Pharma Co., Ltd.
“The investment, together with the license agreement and the pandemic preparedness MOU, reflects Meiji’s confidence in our development capabilities and the potential of our technology platform.”
Joseph Payne, President and Chief Executive Officer of Arcturus Therapeutics
Surrozen, Inc. entered into an underwriting agreement for a public offering of 1,894,540 shares of common stock at a price of $31.67 per share. The company expects to receive gross proceeds of approximately $60 million from the offering, which is scheduled to close on November 16, 2026.
Value
$60M
Counterparty
Morgan Stanley & Co. LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co.
Strategy Inc reported that it sold 2,087,040 shares of Class A Common Stock (MSTR) under its at-the-market offering program between November 9 and November 15, 2026, generating net proceeds of $244.7 million. The company utilized $33.4 million of these proceeds to purchase 485 additional bitcoins and $206.3 million to fund repurchases of its Variable Rate Series A Perpetual Stretch Preferred Stock (STRC).
Medicus Pharma Ltd. entered into a securities purchase agreement for a registered direct offering of 97,973 common shares and 1,646,213 pre-funded warrants for gross proceeds of approximately $3.0 million. Additionally, the company executed a debt-for-equity exchange with Streeterville Capital, LLC, partitioning $10.5 million in principal from an existing secured promissory note into 105,000 non-convertible preferred shares to reduce its debt obligations.
InspireMD, Inc. priced an underwritten public offering of common stock and pre-funded warrants for gross proceeds of approximately $37.5 million. The offering includes 7,342,308 shares of common stock and pre-funded warrants for 50,350,000 shares, each accompanied by Series L warrants. Proceeds are intended for research and development, sales and marketing, and general corporate purposes.
T1 Energy Inc. entered into an equity distribution agreement to establish an at-the-market (ATM) offering program for the sale of up to $100 million of its common stock. The company intends to use the proceeds to fund the construction of Phase 1 of its G2_Austin infrastructure and for general corporate purposes. Roth Capital Partners will serve as the sales agent and receive a commission of up to 3.00% of gross sales proceeds.
Ocean Power Technologies priced a public offering of 6,000,000 shares of common stock and accompanying warrants at a combined price of $0.50 per unit. The company expects to receive gross proceeds of $3.0 million to be used for working capital and general corporate purposes. D. Boral Capital LLC is acting as the exclusive placement agent for the transaction.
Vir Biotechnology entered into an underwriting agreement to sell 15,000,000 shares of common stock at a public offering price of $10.00 per share. The company expects to receive approximately $140.4 million in net proceeds, or $161.5 million if the underwriters exercise their 30-day option to purchase an additional 2,250,000 shares.
Rezolute, Inc. entered into an underwriting agreement for a public offering of 22,040,976 shares of common stock and 3,800,000 pre-funded warrants, expected to raise gross proceeds of approximately $100 million. The financing was led by Frazier Life Sciences and is intended to fund commercialization preparation for ersodetug and general corporate purposes.
DataMEDS AI, Inc. entered into an at-the-market (ATM) sales agreement with Dawson James Securities, Inc. to establish an offering program for its common stock. The company may sell shares from time to time at prevailing market prices, though it is not obligated to make any sales. The Sales Agent will receive a fixed commission of 3.0% of the gross proceeds from any shares sold.
Nakamoto Inc. entered into an amended and restated sales agreement to maintain an at-the-market (ATM) offering program for up to $4.99 billion of common stock. The amendment updates the group of sales agents, adding Muriel Siebert & Co., LLC and Maxim Group LLC while terminating the participation of several previous agents.
CareTrust REIT entered into forward sale agreements for 19,550,000 shares of common stock at an initial forward price of $36.00 per share. The transaction includes an initial 17,000,000 shares and the full exercise of an underwriters' option for an additional 2,550,000 shares. The company intends to physically settle the agreements for cash proceeds by November 12, 2027, to fund future acquisitions and for general corporate purposes.
Value
$704M
Counterparty
BofA Securities, Inc. and Morgan Stanley & Co. LLC
AiRWA Inc. entered into securities purchase agreements with certain investors to sell 1,800,000 shares of common stock at $0.8332 per share. The transaction is expected to generate gross proceeds of approximately $1.5 million for working capital and general corporate purposes. The offering was conducted as a private placement in reliance on Section 4(a)(2) and Regulation D.
Accuray completed a $55 million financing transaction with its primary lender TCW, involving the issuance of 55,000 shares of Series A Convertible Preferred Stock. The deal includes $15 million in new cash capital and the conversion of $40 million of existing debt into equity, significantly deleveraging the balance sheet.
Contango Silver & Gold Inc. entered into a Controlled Equity Offering Sales Agreement to establish an at-the-market (ATM) offering program. The company may sell shares of common stock from time to time with an aggregate offering price of up to $75 million. Cantor Fitzgerald & Co. is acting as the lead agent for the program.
INNOVATE Corp. filed a prospectus supplement to establish a new $50 million at-the-market (ATM) equity offering program through Jefferies LLC. This program replaces a previous registration statement that expired in October 2026 and increases the potential offering amount from $31 million to $50 million. The filing also includes pro forma financial data reflecting the company's recent divestitures of its Broadcasting and DBM Global business units.
Callan JMB Inc. entered into a securities purchase agreement for a private placement of 1,363,639 shares of common stock at $1.10 per share, raising approximately $1.5 million in gross proceeds. The offering was led by Chairman and CEO Wayne Williams and other company insiders, with the purchase price representing a premium to the market price. Proceeds will be used for strategic growth initiatives and general corporate purposes.
Value
$1.5M
Counterparty
Wayne Williams
“Our leadership team is putting its own capital to work because we believe in the path ahead. This is a direct expression of our confidence in the Company’s strategy, and our commitment to building value alongside shareholders.”
Wayne Williams, Chief Executive Officer of Callan JMB
“We believe the strongest signal we can send is to invest our own capital at a price that is at a multiple above the current market, but still at what we perceive to be a discount to the true value of our shares. Investing alongside our shareholders demonstrates our confidence in the company.”
Christopher Shields, Interim Chief Financial Officer
Valor Energy Inc. completed a private placement of 2,145,923 shares of common stock at $2.33 per share, raising gross proceeds of approximately $5.0 million. The company intends to use the proceeds for AI data center project development and general corporate purposes.
Interlink Electronics entered into an at-the-market (ATM) sales agreement with A.G.P/Alliance Global Partners to sell up to $7.2 million of its common stock. The company intends to use the proceeds for working capital, product development, and potential strategic acquisitions. A.G.P will receive a 3.0% commission on the gross sales price of any shares sold under the facility.
Benchmark 2026-V24 Mortgage Trust Capital Raise of $759M
Benchmark 2026-V24 Mortgage Trust completed the issuance and sale of Commercial Mortgage Pass-Through Certificates totaling approximately $759.3 million. The offering included $682.4 million in publicly offered certificates and $76.9 million in privately offered certificates sold to a group of underwriters and initial purchasers led by Goldman Sachs & Co. LLC.
SDR Drone, Inc. entered into an engagement letter with Dawson James Securities, Inc. to act as lead placement agent for a proposed private placement of convertible debt or equity securities. The company is targeting gross proceeds of $2.5 million to $3.0 million to be raised on a best-efforts basis. The agreement includes a $50,000 retainer and a 7.0% placement agent fee for investors introduced by Dawson James.
Volkswagen Auto Lease Trust 2026-C Capital Raise of $745M
Volkswagen Auto Lease Trust 2026-C filed a prospectus for the issuance of $745.15 million in aggregate principal amount of asset-backed notes across five classes (A-1 through A-4). The offering is backed by a pool of auto leases and related vehicles managed by VW Credit, Inc. as sponsor.